


The listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1. (Previously Presented) A compound of formula I



in which

$R^1$  denotes  $(CH_2)_n$ Het1, or  $(CH_2)_n$ Ar,

Het1 is 4-pyridyl, thiophen-2-yl or thiophen-3-yl, which is unsubstituted or mono- or polysubstituted by CN, A and/or Hal,

$R^2$  denotes Het2


Het2 is 2- or 3-furanyl, which is unsubstituted or mono- or polysubstituted by A and/or Hal,

$R^3, R^4$  one of the radicals  $R^3$  or  $R^4$  denotes H, and the other of the radicals  $R^3$  or  $R^4$  denotes  $(CH_2)_nCO_2R^5$ ,  $(CH_2)_nCOHet3$ , CHO,  $(CH_2)_nOR^5$ ,  $(CH_2)_nHet3$ ,  $(CH_2)_nN(R^5)_2$ , CH=N-OA,  $CH_2CH=N-OA$ ,  $(CH_2)_nNHOA$ ,  $(CH_2)_nN(R^5)Het3$ ,  $(CH_2)_nCH=N-Het3$ ,  $(CH_2)_nOCOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OCF_3$ ,  $(CH_2)_nN(R^5)C(R^5)HCOOR^5$ ,  $(CH_2)_nN(R^5)CH_2COHet3$ ,  $(CH_2)_nN(R^5)CH_2Het3$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het3$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)CH_2COOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCOOR^5$ ,  $CH=CHCH_2NR^5Het3$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$  or  $(CH_2)_nN(R^5)Ar$ ,

Het3 is 1-piperidyl, 1-piperazyl, 1-(4-methyl)piperazyl, 4-methylpiperazin-1-ylamine, 1-pyrrolidinyl, 1-pyrazolidinyl, 1-(2-methyl)pyrazolidinyl, 1-imidazolidinyl or 1-(3-methyl)imidazolidinyl or 4-pyridyl, which may be unsubstituted or substituted by one or more CN groups, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, or 2- or 3-pyrazinyl or one of the following groups



and/or  $R^2$  denotes



in which R denotes H or an alkyl group having 1 to 6 C atoms,  
alternatively denotes CH,

or an enantiomer, racemate, or a mixture of enantiomers thereof,  
or a pharmaceutically acceptable salt thereof.

2. (Previously Presented) A compound of formula I according to Claim 1, in which  $R^1$  denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, -ethyl-, -n-propyl- or -n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, -dichloro- or -dicyanophenyl, 3,4,5trifluorophenyl, 3,4,5-trimethoxy- or -triethoxyphenyl, thiophen-2-yl or thiophen-3-yl.


3. (Previously Presented) A compound of formula I according to claim 1, in which  $R^3$  denotes H.

4. (Previously Presented) A compound of formula I according to claim 1, in which  $R^4$  denotes H.

5. (Cancelled)

6. (Previously Presented) A compound of formula I according to claim 1, in which X denotes N.

7. (Previously Presented) A compound according to claim 1, which is of formula IA, IB, IC, ID, IE or IF




in which


$R^1$ ,  $R^2$ , X and A are as defined for the compound of formula I,

or a salt thereof.

8. (Previously Presented) A process for preparing a compound of formula IA according to claim 7




comprising reacting a compound of formula II



or an acid-addition salt thereof, in which

$R^1$  and X have the meanings indicated for the compound of formula IA,

with a compound of formula III




in which

A and  $R^2$  have the meanings indicated for the compound of formula IA,

and/or

a basic compound of formula IA is converted into one of its salts by treatment with an acid.

9. (Previously Presented) A process for preparing a compound of formula IB according to claim 7



in which  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , X and A have the meanings indicated for the compound of formula IB,


comprising reacting a compound of formula II



or an acid-addition salt thereof, in which

$R^1$  and X have the meanings indicated for the compound of formula IB,

with a compound of formula IV



in which

A and  $R^2$  have the meanings indicated for the compound of formula IB,

and/or

a basic compound of formula IB is converted into one of its salts by treatment with an acid.

10. (Previously Presented) A pharmaceutical composition comprising a compound of formula I according to claim 1 and a pharmaceutically acceptable carrier.

11. (Previously Presented) A method for the treatment of anxiety, depression, obsessive-compulsive disorder, male sexual dysfunction, bulimia nervosa, substance abuse, schizophrenia, glaucoma, dementia, pain, memory improvement and promotion of learning, fibromyalgia, migraine, or amyotrophic lateral sclerosis a disease ~~which can be influenced by the binding of a compound of formula I to 5-HT receptors,~~ comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10.

12. (Cancelled)

13. (Previously Presented) A method for antagonizing a 5-HT<sub>2A</sub> receptor, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10.

14. (Cancelled)

15. (Previously Presented) A process for preparing a pharmaceutical composition according to claim 10, comprising mixing together a compound of formula I and a pharmaceutically acceptable carrier.

16. (Currently Amended) A method for the treatment of anxiety, depression, obsessive-compulsive disorder, schizophrenia, glaucoma, dementia, pain, fibromyalgia, migraine, or amyotrophic lateral sclerosis ~~a neurological disorder~~, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10.

17-22. (Cancelled)

23. (Previously Presented) A compound of claim 1, in which R<sup>1</sup> denotes Het1 or Ar.

24-27. (Cancelled)

28. (Previously Presented) A method for antagonizing a 5-HT<sub>2A</sub> receptor in vitro, comprising administering to said 5-HT<sub>2A</sub> receptor an effective amount of a compound according to claim 1.

29. (Currently Amended) A method for the treatment of psychoses,  $[[\bar{x}]]$  comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10.

30. (Previously Presented) A method for the treatment of amyotrophic lateral sclerosis, comprising administering to a subject in need thereof an effective amount

of a pharmaceutical composition according to claim 10.

31. (Previously Presented) A method for the treatment of bulimia, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10.

32. (Previously Presented) A method for the treatment of anorexia nervosa, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10.

33. (Previously Presented) A method for the treatment of premenstrual syndrome, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10.

34. (Previously Presented) A method for positively influencing obsessive compulsive disorder, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to claim 10.

35. (Previously Presented) A compound of formula I according to Claim 1, in which one of the radicals  $R^3$  or  $R^4$  denotes H and the other of the radicals  $R^3$  or  $R^4$  denotes  $(CH_2)_nCO_2R^5$ ,  $(CH_2)_nCOHet3$ ,  $(CH_2)_nHet3$ ,  $(CH_2)_nN(R^5)Het3$ ,  $(CH_2)_nCH=N-Het3$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OCF_3$ ,  $(CH_2)_nN(R^5)C(R^5)HCOOR^5$ ,  $(CH_2)_nN(R^5)CH_2COHet3$ ,  $(CH_2)_nN(R^5)CH_2Het3$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het3$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)CH_2COOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ , or  $(CH_2)_nN(R^5)Ar$ , wherein n is 1, 2, 3, 4 or 5.

36. (Previously Presented) A compound of formula I according to Claim 1, in which one of the radicals  $R^3$  or  $R^4$  denotes H and the other of the radicals  $R^3$  or  $R^4$  denotes  $(CH_2)_nHet3$ , wherein n is 1, 2, 3, 4 or 5.